Cenedella.de

Philman's Pharm: "German Quality, California Ingenuity." Est. 1977


Leave a comment

CANADA – Authorized licensed producers

CANADA LPs

Authorized licensed producers, including licence type, location and contact information

Footnote 1
This licence is for labelling and associated product testing.

Return to footnote1referrer

Footnote 2
This licence is for packaging, labelling, and associated product testing.

Return to footnote2referrer

Number of licences issued

Table: Number of licences issued by province or territory
Province or Territory Number of licences
Nova Scotia 3
New Brunswick 3
Prince Edward Island 1
Newfoundland and Labrador 1
Quebec 11
Ontario 69
Manitoba 2
Saskatchewan 4
Alberta 9
British Columbia 30
Yukon 0
Northwest Territories 0
Nunavut 0
Canada (total) 133
Report a problem or mistake on this page


The UN Commission of Narcotic Drugs (CND) will receive the final scheduling recommendations of the World Health Organization (WHO) on cannabis in all forms to the 187 Member States at the United Nations Office on Drugs and Crime (UNODC) headquarters in Vienna, Austria on December 5-7, 2018.

More info here:
==========
Philip J. Cenedella IV
www.cenedella.de
Skype: philip.j.cenedella
Phones:   +49.151.720.17652
+1.888.206.3264 USA

German Tax No.: 38/108/04462

VAT No.:  DE313501847

CONFIDENTIAL COMMUNICATION: E-mails from this individual normally contain confidential and privileged material, and are for the sole use of the intended recipient. Use or distribution by an unintended recipient is prohibited. If you believe that you received this e-mail in error, please delete. Electronic Communications Privacy Act, 18 U.S.C. 2510-2521. Thanks.  Copyright © 2018 GERMAN PATIENT ROUNDTABLE – All Rights Reserved.   ** Your personal data will never be shared with anyone, …never.  The German Patient Roundtable is dedicated to Ras Manos, R.I.P.


German cultivation tender for medical marijuana stopped in its tracks…..and information on the GERMAN PATIENT ROUNDTABLE www.germanpatientroundtable.de

https://www.cannabisindustryjournal.com/news_article/german-court-stops-pending-cannabis-cultivation-bid-on-technical-fault/

German Patients are Going to be on the Front Lines of This Discussion

The difficulties that German patients have already faced in obtaining a drug that is now legal in their own country for medical use (and even for recreational purposes across an open border in Holland) are legion. While to a certain extent, German patients are in the same boat as patients elsewhere and their problems, in fact, there are still huge access issues that remain. For starters, the drug is much more expensive here, so those without health insurance approval face bills of about $3,000 per month. Why the eye-watering price? All medical grade cannabis is still imported, although increasingly this is now just via other EU countries, not just from Canada.

“One of the reasons we organized the national German Patient Roundtable is to give patients a voice in all of this supply and demand discussion and to help BfArM and others formulate workable solutions for all,” responded Philip Cenedella IV when reached for a response by CIJ. Cenedella, an American expat and the organizer of the Roundtable, a nationally focussed, umbrella group that is kicking off its campaign this year, spoke for many who are far from court and boardrooms where the decisions are being made.

Philip Cenedella
Philip Cenedella, pictured left, at the Deutsche Hanfverband (DHV) conference in Berlin last November.
Photo: @MedPayRx, Instagram

“While there are very talented firms who will now take up this discussion with the government and reissue a response for the tender, what we continue to see on the ground is that patients simply do not have the access granted them in the law which was passed over a year ago,” Cenedella says, with more than a note of frustration. “We again are calling on all government officials, industry executives and patient advocates to band together to immediately establish workable protocols that directly help the patients.”

Indeed, despite the frustration and delay, if not new costs and opportunities that this decision creates, one thing is very clear on the ground here. The current status quo is unacceptable. That alone should also put pressure on the powers that be to remedy the situation as quickly as possible. And via several routes, including widening import quotas or even issuing new licenses as a new solution to domestic cultivation is implemented.

“Patients are not being served and do not have access to a medicine that has been proven to improve lives,” says Cenedella. “Our simple request is for BfArM to finally invite patients into their discussions, to work with patients to formulate workable cultivation and distribution solutions, and we humbly request that this happen now before they go down another dead-end road, ending in another court defeat, and resulting in even more delays to the patients that are still lacking the care afforded them by the German Federal Court’s decision of 2017.”

 

For more info:

http://www.germanpatientroundtable.de

 


Deutsche Bahn: Cannabis medicine at railway stations is permitted – from DHV

https://hanfverband.de/nachrichten/news/deutsche-bahn-cannabismedizin-auf-bahnhoefen-ist-erlaubt Published: 24 August 2017 – 11:08By: Florian Rister

Can cannabis patients take their medicine at stations? Are you allowed to smoke cannabis in designated smoking areas? These questions have not only been concerned with many affected and even railway workers since the amendment of the Act in March. The DHV has followed up at the German Railroad and received answers!

We are currently aware of a case in which a cannabis patient was given a ban on smoking in the smoking area of ​​a station due to the smoking of cannabis. It seemed all the more exciting to get an official statement from Deutsche Bahn. Because by the re-classification of medical cannabis as a classic Annex III narcotic, this actually corresponds to the same status as many other drugs also. It is therefore not surprising that the Deutsche Bahn provides in its opinion: Legal cannabis medicine prescribed and taken is permitted at railway stations, also smoked in the smoking zone!

Here are our related questions and the complete answers from DB:

1.) The building rules for DB stations prohibit “trade with and consumption of drugs and narcotics”. Does this apply in principle to prescribed anesthetics from Appendix III BtmG?

On the basis of the relevant legal bases, such as the BGB (German Civil Code) as well as other sources, the building rules for passenger stations reflect the conditions of use of all station visitors. The control content is based on the faulty behavior of station attendants perceived on the spot and are intended to ensure that all station visitors behave equally and in a manner which is reckless in DB’s railway stations. The regulation you referred to relates, as in the BtmG, to the anesthetics of Appendix III in principle. The exception to this is provided by medically prescribed anesthetics, which were prescribed by a physician according to the provisions of the BtmG §13 (1). In this case, we believe that the intended use, Which is detectable by the corresponding prescriptions. This means in practice, as long as pharmacies documented the entitlement to the funds from Annex III to prove and consumers according to the enclosed medical regulation the legal authority to the consumption of the anesthetics can prove and from consumption no danger for the life and / or the safety of the Railway undertakings, this is not prohibited by the rules of the DB railway stations.
2.) Can patients with a prescription for cannabis take this orally in railway stations or other premises of the DB, eg as a drop, drink or pastry?

Provided that the requirements of § 13 (1) are met and the consumer can prove this and does not create any danger to life or limb through the use, the consumption is permitted in public areas of the passenger stations. For non-public areas of DB or third parties in the station, eg travel centers, office complexes or even rental units in railway stations, the respective responsible owners can define different regulations at their own discretion. This is beyond the competence of DB Station & Service AG.
3.) Can patients with a prescription for cannabis smoke this in designated smoking areas on DB stations?

If the requirements of § 13 para. 1 are fulfilled and the consumer is able to prove this and the risk of death is not a risk to life and limb, the patient may smoke in the designated smoking areas of the DB Cannabis stations by means of smoking. Provided that he does so in a provocative manner or for other station visitors of an inconvenient form, we reserve the right to use the relevant safety authorities as the owner of the house. If a consumer is unable or can not prove his right to use against our employees or on behalf of the DB companies on demand, we reserve the right to initiate domestic measures and to contact the relevant safety authorities to clarify the facts.
Subjects:
German Hemp Association
Cannabis as medicine
Panorama & Strange
Germany – General information
Special Topics:
start page
Cannabis as medicine law (2016)


Top 9 Active CBD Clinical Trials To Date – by Joe Powers

Top 9 Active CBD Clinical Trials To Date
by Joe Powers
What CBDs (Cannabidiols) Are Currently In Clinical Trials And What Results Are They Proving
As CBD (cannabidiol) comes into the light of the public eye, the curiosity of government researchers continues to grow. Through this growth of interest comes with it funding for real science and research into the mysteries of cannabis sativa and specifically, CBD Cannabidiol.

How many clinical trials are currently active?
Are potential participants able to sign up?
Will their clinical trials be recruiting soon?
Clinicaltrials.gov does an excellent job of organizing the data and presenting it in an easy to find and understand manner. On this website, you’re able to do advanced searches to locate clinical trials which are actively enrolling (cannabidiol) and will soon be recruiting (cannabidiol). Make sure you do also search for the search term CBD; actively enrolling (CBD) & soon recruiting (CBD). When you search for cannabidiol you’ll on receive 20+ results. While searching for CBD will yield 80+ results.

A few of the upcoming CBD clinical trials include:

Autistic Disorder
Anxiety
Chronic Pain
Epilepsy
Infantile Spasms
Lung Cancer
Multiple Sclerosis
Parkinsons
Posttraumatic Stress Disorder
Schizophrenia
And several more
As of now, there are 22+ active clinical trials researching the effects of CBD (cannabidiol).
A few of the 22+ conditions currently in active clinical trials are as follows:

Click here to see full CBD clinical trials list for either CBD or Cannabidiol search terms.

Cannabis Use Disorder
Effects Of CBD In Healthy Humans
Epilepsy; Drug Interaction, Pediatric, & Drug Resistant
Opiate Addiction
Sturge-Weber Syndrome
Seizures
Infantile Spasms
Advanced Parkinson’s Disease
Type 1 Diabetes
And more.
What results are they proving? What new information is currently available from new studies?
As of now, there are no results posted of any studies going on.
CUD (Cannabis Use Disorder)
First of all, the active clinical trial for cannabis use disorder started in March 2014. This study wants to investigate a “novel treatment” for those who want to quit cannabis and meet the criteria for moderate use. Stage 1 of the trial is scheduled to wrap up and collected its final data for the primary outcome July 2017. In the first stage, they will identify the MED (Most Effective Dose), by taking an oral CBD, to lower cannabis abuse. Next, in stage 2, they will then decide if the MED in stage 1 is an effective treatment for curing CUD.

Effects Of CBD In Healthy Humans
This particular clinical trial is studying healthy adults between the age of 18 – 55 years of age with 75 participants enrolled. Beginning in 2010 and is estimated to have all their primary data by July 2017. Most noteworthy, participants are injected with active Delta-9-THC (0.035mg/Kg) over a 20-minute time frame. This size of the dose is the same amount of THC you’d receive if you were to smoke about a half to a whole cannabis joint. What will be measured in this study are specific behaviors at time intervals of; 15,80, 240 days. The subjective effects to be studied involve perception alterations and effects of mental processes. Mental functions will be assessed using various visual & analog scales among others.

Epilepsy
There are currently three clinical trials researching the effects of CBD and epilepsy.
One clinical trial is investigating CBD with epileptic children between 1 and 18 years. Phase 1 is determining the optimal dose of CBD rich cannabis extract to treat Dravet syndrome, a severe form of epilepsy. High environmental climates and fever are two of the main stimulants triggering episodes. Gathering the primary data will take an initial 20 week and will continue to follow up for another 64 weeks. During this time, they will evaluate adverse effects and document side effects through questionnaires.

Second epilepsy and CBD clinical trials will be investigating the interactions between Clobazam and CBD. With the third and final CBD and epilepsy clinical trial involving CBD and drug resistant epilepsy with children 2 – 19.

Opiate Addiction
As opiate addiction study moves into phase 2, they will be gathering data on effectiveness while continuing to evaluate safety. Research here is focusing on utilizing CBD to modulate the craving for opiates by inhibiting drug-seeking behavior. This clinical trial is necessary because, despite the abundance of alternative therapies available to treat opioid dependency, most patients end up relapsing. The study set to complete in October 2017.

Seizures & Sturge-Weber Syndrome
SWS (Sturge-Weber Syndrome) is a rare neurological and skin disorder. Some children with this syndrome don’t have any symptoms while others have severe developmental delays and seizures. GW Pharmaceuticals Ltd. & Faneca 66 Foundation began clinical trials in December 2014 to determine the optimal dosage of CBD to treat SWS, a drug resistant form of epilepsy. They are currently in phase 2 and estimating trial completion in January 2018 while measuring the change in seizure frequency.

One more active seizure CBD clinical trial is an open-trial, in multiple locations, researching the long-term safety CBD with the treatment resistant seizure. Currently in phase 3 and estimated completion in December 2017

Infantile Spasms (IS)
The 9th and the final active CBD clinical trial is studying Infantile Spasms (IS) in children between 6 and 36 months of age. Infantile Spasms (IS) is described as a rare and terrible form of epilepsy that usually strikes children in their first year of life. There’s an even more urgent need for this trial because the currently available medicines are not helping and the children are remaining sick. Now, in phase 2 and will continue researching the safety and efficacy of COS (Cannabidiol Oral Solution) in treating IS.

As a result, there are 22+ active CBD clinical trials, 230+ completed clinical trials, and 110+ clinical trials either in open enrollment or getting ready to open up to recruiting for CBD clinical trials.

[Featured image credit- CannaSOS]

Joe Powers | August 28, 2017 at 12:06 pm | Tags: cannabidiol, Cannabis, CBD, Clinical Trials, Epilepsy, opiate addiction, Seizure | Categories: Health, Science | URL: http://wp.me/p8nEcz-zk


CW Hemp, PlusCBD Oil, HempMeds (RHSO), Elixinol and CannazALL are the top 5 CBD brands online, according to a new report by Tampa, Florida-based Brightfield Group, a market research firm that specializes in the cannabis industry. The report (cost: $395) projects the hemp-derived CBD market will hit $1 billion by 2022, noting CBD sales hit $170 million in 2016 and suggesting 55% compound annual growth over the next five years will cause the market to crack the billion-dollar mark.


Europe’s market potential for cannabidiol (CBD) is pegged at around €2 billion as a treatment for chronic diseases, according to a new report by nova-Institute and HempConsult (both of Germany), who probed the market for non-psychotropic CBD, increasingly in demand as a food supplement and pharmaceutical.